Contralateral choroiditis secondary to combination therapy with simeprevir, sofosbuvir and ribavirin
-
González Freire, Lara [1] ; María Encina García Mayo ; Vázquez Blanco, Silvia ; Ana Belén Veiga Villaverde ; Crespo Diz, Carlos
-
[1] University Hospital Complex of Pontevedra
-
- Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 19, Nº. 4, 2017, págs. 291-293
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Contralateral choroiditis is an inflammation of the back portion of the eye, whose treatment consists of the administration of systemic corticoids. In this paper, we describe the case of a patient with Chronic Hepatitis C and Human Immunodeficiency Virus, who was diagnosed with contralateral choroiditis after developing ocular alterations associated with loss of visual acuity nine weeks after receiving combination therapy with simeprevir, sofosbuvir and ribavirin, as a result of which the treatment had to be discontinued, achieving a significant improvement of the ocular pathology. One year later, and after an increase in the viral load was detected, the patient was hospitalized in order to initiate a new line of treatment with ledipasvir/sofosbu- vir, monitored by the Ophthalmology Service through directly observed therapy for a week and, subsequently, on a biweekly and monthly basis in order to keep track of potential ophthalmic events. He completed 24 weeks of treatment successfully. Ophthalmic events are not described as adverse events in the datasheets of direct-acting antivirals for the treatment of Hepatitis C Virus infections, and are classified as rare in the datasheet of ribavirin in combination with interferon alpha. This case seems suggestive of a causal relationship between simeprevir and/ or ribavirin and ophthalmic events
